Pulmonary Embolism
Conditions
Brief summary
Phase II trial of TS23
Detailed description
Evaluation of safety and thrombolytic effect of ascending doses of TS23 in subjects with intermediate-risk (sub-massive) acute pulmonary embolism (PE)
Interventions
DRUGTS23
Monoclonal antibody to a2-antiplasmin
DRUGPlacebo
Placebo
Sponsors
Translational Sciences, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female subjects, age \>18 years; 2. PE involving a segmental or more proximal pulmonary artery confirmed by CTPA scan and with an onset of symptoms not more than 5 days prior to diagnosis; 3. Subject is hemodynamically stable with a systolic blood pressure (SBP) \>90 mm Hg; 4. Subject has evidence of RV dysfunction as indicated by a right ventricular-to-left ventricular (RV/LV) diameter ratio \> 0.9 on CTPA scan (measuring the minor axis of the right and left ventricle in the transverse plane), prior to the initiation of study drug administration.
Exclusion criteria
1. Subjects for whom thrombolytic therapy or thrombectomy is planned; or subjects with history of administration of thrombolytic agents within the previous 4 days; 2. Subjects receiving ≥ 48 hours of therapeutic doses of heparin or low molecular weight heparin (LMWH) or other anticoagulant therapy immediately prior to randomization; 3. Subjects with contraindications to SOC therapies such as unfractionated heparin or LMWH or oral anticoagulant, or any of the excipients (including study drug excipients); 4. Subjects who are considered at very high risk of bleeding: 1. Known coagulation disorder with history of pathologic bleeding tendencies 2. Subjects with prior intracranial hemorrhage, known arteriovenous malformation or aneurysm of the brain, or evidence of active bleeding; 3. Subjects with a history of major surgery, clinically significant head trauma (in the opinion of the Principal Investigator), or stroke in the past 3 months prior to randomization; 4. Subjects with uncontrolled hypertension defined as SBP ≥180 mm Hg and/or diastolic BP (DBP) ≥110 mm Hg at randomization 5. Subjects requiring concomitant dual antiplatelet therapy 5. Subjects with Creatinine Clearance (CrCL) \< 30 mL/min or serum creatinine ≥ 2.5 mg/dL; 6. Subjects with hemoglobin \< 8.0 g/dL; 7. Subjects with a platelet count \< 100,000/µL; 8. Subjects with acute or persistent hepatitis or diagnosed active liver disease or with elevation of liver enzymes: Alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 3 x upper limit of normal (ULN); 9. Subjects with known history of testing positive for Hepatitis B antigen or Hepatitis C antibody; 10. Subjects with known history of testing positive for the human immunodeficiency virus (HIV); 11. Subjects with life-expectancy \< 6 months; 12. Female subjects of child bearing potential with a positive pregnancy test or who are lactating, or unwilling to use highly effective methods of contraception. Highly effective methods of birth control include combination hormonal therapy (estrogen and progresterone), contraceptives administered orally, intravaginally or transdermally, progesterone-only contraceptives administered orally, by injection or implantation, use of an intrauterine device (IUD), intrauterine hormone- releasing system (IUS), bilateral tubal occlusion, partner vasectomy or sexual abstinence; 13. Subjects currently participating in another investigational study or who have participated in an investigational drug study within 30 days (or longer depending on the half-life of the investigational drug; should allow at least five half-life of the investigational drug) prior to randomization.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| RV/LV | 48 hours after treatment | Ratio of the right to left ventricle dimensions on CT perfusion angiogram (CTPA) |
| Safety- Bleeding | within 7 days of treatment | Frequency of major or clinically significant bleeding |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Thrombus dissolution | 48 hours after treatment | Change in modified Miller Score |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORNils Nickel, MD
University of Texas
Outcome results
None listed